We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+11.35%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$81.6B
AUM Growth
+$7.7B
(+10%)
Cap. Flow
+$798M
Cap. Flow
% of AUM
0.98%
Top 10 Holdings %
Top 10 Hldgs %
23.85%
Holding
3,095
New
53
Increased
1,513
Reduced
1,408
Closed
84
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$65.3M |
| 2 |
Amazon
AMZN
|
+$50M |
| 3 |
Tesla
TSLA
|
+$30.5M |
| 4 |
Alphabet (Google) Class A
GOOGL
|
+$26.6M |
| 5 |
EPAM Systems
EPAM
|
+$26.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
KSU
Kansas City Southern
KSU
|
+$39.1M |
| 2 |
HRC
HILL-ROM HOLDINGS, INC.
HRC
|
+$31.2M |
| 3 |
XEC
CIMAREX ENERGY CO
XEC
|
+$23.4M |
| 4 |
Berkshire Hathaway Class B
BRK.B
|
+$21.9M |
| 5 |
SBNY
Signature Bank
SBNY
|
+$17.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.54% |
| 2 | Financials | 13.15% |
| 3 | Healthcare | 12.95% |
| 4 | Consumer Discretionary | 12.27% |
| 5 | Industrials | 8.9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BNFT
2651
DELISTED
Benefitfocus, Inc.
BNFT
| $353K | ﹤0.01% |
33,141
-7,354
| -18% | -$78.9K |
|
2652
Arbutus Biopharma
ABUS
$915M
| $352K | ﹤0.01% |
90,535
+71
| +0.1% | +$276 |
|
|
IMA
2653
ImageneBio Inc
IMA
$64.6M
| $352K | ﹤0.01% |
+2,342
| New | +$380K |
|
2654
Xometry
XMTR
$5.34B
| $352K | ﹤0.01% |
6,861
-142
| -2% | -$7.3K |
|
|
XXII
2655
22nd Century Group
XXII
$1.48M
| – | – |
0
| – | – |
|
2656
Precision BioSciences
DTIL
$207M
| $351K | ﹤0.01% |
1,582
-24
| -1% | -$6.7K |
|
2657
Orrstown Financial Services
ORRF
$838M
| $351K | ﹤0.01% |
13,932
-14
| -0.1% | -$339 |
|
2658
Relmada Therapeutics
RLMD
$527M
| $351K | ﹤0.01% |
15,584
-242
| -2% | -$5.38K |
|
2659
Oramed Pharmaceuticals
ORMP
$179M
| $349K | ﹤0.01% |
24,435
+2,212
| +10% | +$46.2K |
|
2660
SoundThinking
SSTI
$103M
| $347K | ﹤0.01% |
11,754
+3,146
| +37% | +$110K |
|
|
MCBC
2661
DELISTED
Macatawa Bank Corp
MCBC
| $347K | ﹤0.01% |
39,290
+435
| +1% | +$3.72K |
|
|
PVBC
2662
DELISTED
Provident Bancorp
PVBC
| $346K | ﹤0.01% |
18,608
+645
| +4% | +$11.6K |
|
|
IAS
2663
DELISTED
Integral Ad Science
IAS
| $345K | ﹤0.01% |
15,544
+1,299
| +9% | +$29.6K |
|
|
ESTE
2664
DELISTED
Earthstone Energy Inc. Class A Common Stock
ESTE
| $345K | ﹤0.01% |
31,497
+1,329
| +4% | +$14.2K |
|
2665
Krispy Kreme
DNUT
$577M
| $342K | ﹤0.01% |
18,069
+2,743
| +18% | +$40.3K |
|
2666
Verastem
VSTM
$610M
| $342K | ﹤0.01% |
13,914
-272
| -2% | -$8.58K |
|
2667
Lexicon Pharmaceuticals
LXRX
$1.1B
| $341K | ﹤0.01% |
86,660
+2,669
| +3% | +$13K |
|
|
LBC
2668
DELISTED
Luther Burbank Corporation Common Stock
LBC
| $341K | ﹤0.01% |
24,323
-550
| -2% | -$7.71K |
|
|
ENFN
2669
DELISTED
Enfusion, Inc.
ENFN
| $340K | ﹤0.01% |
+16,255
| New | +$328K |
|
|
SOVO
2670
DELISTED
Sovos Brands, Inc. Common Stock
SOVO
| $340K | ﹤0.01% |
+22,585
| New | +$337K |
|
|
AERI
2671
DELISTED
Aerie Pharmaceuticals
AERI
| $340K | ﹤0.01% |
48,426
+493
| +1% | +$5.16K |
|
2672
Phathom Pharmaceuticals
PHAT
$692M
| $338K | ﹤0.01% |
17,207
-247
| -1% | -$5.81K |
|
2673
Century Casinos
CNTY
$34M
| $337K | ﹤0.01% |
27,630
-1,214
| -4% | -$17.1K |
|
2674
Cogent Biosciences
COGT
$7.24B
| $333K | ﹤0.01% |
38,855
-740
| -2% | -$6.43K |
|
|
IHC
2675
DELISTED
Independence Holding Company
IHC
| $331K | ﹤0.01% |
5,832
-867
| -13% | -$46.3K |
|
Similar funds
VAM
RhumbLine Advisers's Q4 2021 Portfolio in Review
As of Q4 2021, RhumbLine Advisers held 3,095 positions worth $81.6B, up 10% from $73.9B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Trading was light in Q4 2021: portfolio turnover was 4.4%. RhumbLine Advisers opened 53 new positions and exited 84, leaving the 3,095-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 24% a quarter earlier, followed by Financials and Healthcare.
- RhumbLine Advisers's largest Q4 2021 buy was Rivian: 125,331 shares worth $13M.
- RhumbLine Advisers added most to Microsoft in Q4 2021, an estimated $65.3M increase.
- RhumbLine Advisers's biggest Q4 2021 reduction was Berkshire Hathaway Class B, cutting an estimated $21.9M.
- RhumbLine Advisers fully exited Kansas City Southern in Q4 2021, selling an estimated $39.1M.
- RhumbLine Advisers's ten largest holdings make up 24% of its $81.6B portfolio in Q4 2021.
- RhumbLine Advisers opened 53 new positions and closed 84 in Q4 2021.
- RhumbLine Advisers's portfolio value rose 10% quarter-over-quarter to $81.6B.
Based on RhumbLine Advisers's 13F filing for Q4 2021, filed 10 Feb 2022.